Biotech

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 (also known as RX518), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor …

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 (also known as RX518), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non-small cell lung cancer (NSCLC).

As quoted in the press release:

“These preliminary data demonstrate CK-101 is well-tolerated at the doses tested while also demonstrating encouraging anti-tumor activity, particularly in treatment-naïve EGFR mutation-positive lung cancer patients,” said Melissa L. Johnson, M.D., Associate Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, PLLC, and study chair of the Phase 1/2 trial.

“The data to date demonstrate CK-101’s potential to be a highly effective mutant-selective EGFR inhibitor with the potential for a differentiated safety profile,” said James F. Oliviero, President and Chief Executive Officer of Checkpoint Therapeutics. “We look forward to continuing to advance CK-101 towards a pivotal Phase 3 trial next year, positioning CK-101 to potentially be only the second third-generation EGFR inhibitor to enter the market.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX19837.25-52.81
TSXV700.90-10.29
DOW31834.11-326.63
S&P 5003935.18-65.87
NASD11364.24-373.44
ASX7051.20-69.50

COMMODITIES

Commodities
Gold1852.77+19.39
Silver21.56+0.30
Copper4.210.00
Palladium2034.00-3.00
Platinum999.00+36.00
Oil105.63-0.08
Heating Oil3.77+0.02
Natural Gas7.67+0.03

DOWNLOAD FREE REPORTS

×